HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.
HTG EdgeSeq DLBCL Cell of Origin Assay and the HTG EdgeSeq Lung Fusions RUO Assay now available for use on Thermo Fisher Scientific Ion Torrent NGS platform TUCSON, Ariz. , July 15, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is
TUCSON, Ariz. , July 08, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the release of its HTG EdgeSeq TM Reveal data analytics software, version 1.2.0.
TUCSON, Ariz. , July 01, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that it presented its technology in an oral presentation at the annual WIN Symposium meeting for personalized
TUCSON, Ariz. , May 24, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that on May 22, 2019 the Compensation Committee of its Board of Directors granted inducement stock options to
Call scheduled for today, May 9, at 4:30pm ET TUCSON, Ariz. , May 09, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31, 2019
